Subscribe via the sign-up block at the bottom of this page
Start slowly - ideally once a day, and no more than twice a day
Reported safety observations from published studies indicate that intravenous ALA has generally been well tolerated under the specific doses and conditions studied, although adverse events have been documented and can vary depending on dose, patient characteristics, and study design
Pharmacokinetics, dose-response, and safety at these regimens havent been characterized in major peer-reviewed clinical trials
The public repository of xenografts enables discovery and randomized Phase II-like trials in mice
50 mg / 5 mL = 10 mg/mL 2,000 mcg / 10,000 mcg per mL = 0.2 mL = 20 U-100 units 1,000 mcg / 10,000 mcg per mL = 0.1 mL = 10 U-100 units GHK-Cu 100 mg vial with 5 mL example A larger 100 mg vial mixed with 5 mL gives 20 mg/mL, or 20,000 mcg/mL double the strength of the 50 mg example